Pactimibe free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329597

CAS#: 189198-30-9 (free base)

Description: Pactimibe, also known as CS-505, is a ACAT inhibitor. Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Pactimibe reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Pactimibe inhibits cholesterol absorption from the intestine, reduces cholesteryl ester formation in the liver, and enhances its elimination from the body. The Triton WR-1339 experiment showed that pactimibe inhibited secretion of very low density lipoprotein cholesterol from the liver. These results suggest that pactimibe is likely to have multiple mechanisms of action responsible for its effectiveness in reducing serum cholesterol.

Chemical Structure

img
Pactimibe free base
CAS# 189198-30-9 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 329597
Name: Pactimibe free base
CAS#: 189198-30-9 (free base)
Chemical Formula: C25H40N2O3
Exact Mass: 416.30
Molecular Weight: 416.606
Elemental Analysis: C, 72.08; H, 9.68; N, 6.72; O, 11.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 608510-47-0 (sulfate)   189198-30-9 (free base),  

Synonym: Pactimibe; CS-505; CS505; CS 505.

IUPAC/Chemical Name: (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid

InChi Key: TXIIZHHIOHVWJD-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H40N2O3/c1-7-8-9-10-11-12-14-27-15-13-19-17(2)20(16-21(28)29)18(3)22(23(19)27)26-24(30)25(4,5)6/h7-16H2,1-6H3,(H,26,30)(H,28,29)

SMILES Code: O=C(O)CC1=C(C)C2=C(N(CCCCCCCC)CC2)C(NC(C(C)(C)C)=O)=C1C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 416.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yoshinaka Y, Shibata H, Kobayashi H, Kuriyama H, Shibuya K, Tanabe S, Watanabe T, Miyazaki A. A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. Atherosclerosis. 2010 Nov;213(1):85-91. doi: 10.1016/j.atherosclerosis.2010.08.048. Epub 2010 Aug 19. PMID: 20843517.


2: Ohta M, Takahashi K, Kasai M, Shoji Y, Kunishiro K, Miike T, Kanda M, Mukai C, Shirahase H. Novel tetrahydroisoquinoline derivatives with inhibitory activities against acyl-CoA: cholesterol acyltransferase and lipid peroxidation. Chem Pharm Bull (Tokyo). 2010 Aug;58(8):1066-76. doi: 10.1248/cpb.58.1066. PMID: 20686261.


3: Takahashi K, Ohta M, Shoji Y, Kasai M, Kunishiro K, Miike T, Kanda M, Shirahase H. Novel acyl-CoA: cholesterol acyltransferase inhibitor: indoline- based sulfamide derivatives with low lipophilicity and protein binding ratio. Chem Pharm Bull (Tokyo). 2010 Aug;58(8):1057-65. doi: 10.1248/cpb.58.1057. PMID: 20686260.


4: Shoji Y, Takahashi K, Ohta M, Kasai M, Kunishiro K, Kanda M, Yogai S, Takeuchi Y, Shirahase H. Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor: Effects of introducing a methanesulfonamide group on physicochemical properties and biological activities. Bioorg Med Chem. 2009 Aug 15;17(16):6020-31. doi: 10.1016/j.bmc.2009.06.047. Epub 2009 Jun 27. PMID: 19608421.


5: Parini P, Eriksson M, Rudel LL. Carotid atherosclerosis progression and ACAT inhibition. JAMA. 2009 Jul 15;302(3):255; author reply 256-7. doi: 10.1001/jama.2009.1000. PMID: 19602681.


6: Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem. 2009;16(21):2661-805. doi: 10.2174/092986709788681985. PMID: 19601803.


7: Atherosclerosis drug fails to meet Phase III trial end point. Nat Rev Drug Discov. 2009 May;8(5):348. doi: 10.1038/nrd2879. PMID: 19404306.


8: Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA; CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18;301(11):1131-9. doi: 10.1001/jama.301.11.1131. PMID: 19293413.


9: Kotsuma M, Tokui T, Freudenthaler S, Nishimura K. Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528. Int J Clin Pharmacol Ther. 2008 Nov;46(11):545-55. doi: 10.5414/cpp46545. PMID: 19000552.


10: Takahashi K, Kasai M, Ohta M, Shoji Y, Kunishiro K, Kanda M, Kurahashi K, Shirahase H. Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid. J Med Chem. 2008 Aug 14;51(15):4823-33. doi: 10.1021/jm800248r. Epub 2008 Jul 12. PMID: 18620381.


11: Kotsuma M, Hanzawa H, Iwata Y, Takahashi K, Tokui T. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos. 2008 Sep;36(9):1938-43. doi: 10.1124/dmd.108.020776. Epub 2008 Jun 4. PMID: 18524873.


12: Kotsuma M, Tokui T, Freudenthaler S, Nishimura K. Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. Drug Metab Dispos. 2008 Aug;36(8):1505-11. doi: 10.1124/dmd.108.021394. Epub 2008 Apr 30. PMID: 18448569.


13: Kotsuma M, Tokui T, Ishizuka-Ozeki T, Honda T, Iwabuchi H, Murai T, Ikeda T, Saji H. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528. Drug Metab Dispos. 2008 Mar;36(3):529-34. doi: 10.1124/dmd.107.018853. Epub 2007 Dec 3. PMID: 18056254.


14: A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments. Heart Advis. 2006 Feb;9(2):4-5. PMID: 17763560.


15: Wiklund O. Nya medel mot ateroskleros testas. Oroande fynd med ACAT-hämmare, som tycks ha proaterogena effekter [New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects]. Lakartidningen. 2006 Oct 25-31;103(43):3270. Swedish. PMID: 17117657.


16: Nicholls SJ, Sipahi I, Schoenhagen P, Wisniewski L, Churchill T, Crowe T, Goormastic M, Wolski K, Tuzcu EM, Nissen SE; ACTIVATE Investigators. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. Am Heart J. 2006 Jul;152(1):67-74. doi: 10.1016/j.ahj.2005.10.025. PMID: 16824833.


17: Kitayama K, Koga T, Inaba T, Fujioka T. Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor. Eur J Pharmacol. 2006 Aug 14;543(1-3):123-32. doi: 10.1016/j.ejphar.2006.05.036. Epub 2006 Jun 2. PMID: 16814766.


18: Rudel LL, Farese RV Jr. ACAT inhibition and the progression of coronary atherosclerosis. N Engl J Med. 2006 Jun 15;354(24):2616-7; author reply 2616-7. doi: 10.1056/NEJMc061094. PMID: 16775245.


19: Kitayama K, Tanimoto T, Koga T, Terasaka N, Fujioka T, Inaba T. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti- atherosclerotic potency of pactimibe. Eur J Pharmacol. 2006 Jul 1;540(1-3):121-30. doi: 10.1016/j.ejphar.2006.04.022. Epub 2006 Apr 29. PMID: 16730694.


20: Kitayama K, Koga T, Maeda N, Inaba T, Fujioka T. Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Eur J Pharmacol. 2006 Jun 6;539(1-2):81-8. doi: 10.1016/j.ejphar.2006.03.078. Epub 2006 Apr 7. PMID: 16690054.